ID HXB13_HUMAN Reviewed; 284 AA. AC Q92826; B2R878; Q96QM4; Q99810; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 19-JUL-2004, sequence version 2. DT 27-MAR-2024, entry version 203. DE RecName: Full=Homeobox protein Hox-B13; GN Name=HOXB13; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=8756292; DOI=10.1242/dev.122.8.2475; RA Zeltser L.M., Desplan C., Heintz N.; RT "Hoxb-13: a new Hox gene in a distant region of the HOXB cluster maintains RT colinearity."; RL Development 122:2475-2484(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9665387; DOI=10.1046/j.1523-1747.1998.00238.x; RA Stelnicki E.J., Arbeit J., Cass D.L., Saner C., Harrison M., Largman C.; RT "Modulation of the human homeobox genes PRX-2 and HOXB13 in scarless fetal RT wounds."; RL J. Invest. Dermatol. 111:57-63(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Prostate; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Prostate; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] {ECO:0007744|PDB:2CRA} RP STRUCTURE BY NMR OF 217-273. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the homeobox domain of human homeo box B13."; RL Submitted (NOV-2005) to the PDB data bank. RN [8] {ECO:0007744|PDB:5EDN, ECO:0007744|PDB:5EEA, ECO:0007744|PDB:5EG0} RP X-RAY CRYSTALLOGRAPHY (2.19 ANGSTROMS) OF 209-284 IN COMPLEX WITH MEIS2 AND RP DNA, SUBUNIT, AND DNA-BINDING. RA Morgunova E., Yin Y., Jolma A., Popov A., Taipale J.; RT "Molecular basis of recognition of two distinct DNA sequences by a single RT transcription factor."; RL Submitted (OCT-2015) to the PDB data bank. RN [9] {ECO:0007744|PDB:5EF6, ECO:0007744|PDB:5EGO} RP X-RAY CRYSTALLOGRAPHY (2.54 ANGSTROMS) OF 217-278 IN COMPLEX WITH MEIS1 AND RP METHYLATED DNA, SUBUNIT, AND DNA-BINDING. RX PubMed=28473536; DOI=10.1126/science.aaj2239; RA Yin Y., Morgunova E., Jolma A., Kaasinen E., Sahu B., Khund-Sayeed S., RA Das P.K., Kivioja T., Dave K., Zhong F., Nitta K.R., Taipale M., Popov A., RA Ginno P.A., Domcke S., Yan J., Schubeler D., Vinson C., Taipale J.; RT "Impact of cytosine methylation on DNA binding specificities of human RT transcription factors."; RL Science 356:0-0(2017). RN [10] RP VARIANT MET-41. RX PubMed=11857506; DOI=10.1002/tera.10009; RA Kosaki K., Kosaki R., Suzuki T., Yoshihashi H., Takahashi T., Sasaki K., RA Tomita M., McGinnis W., Matsuo N.; RT "Complete mutation analysis panel of the 39 human HOX genes."; RL Teratology 65:50-62(2002). RN [11] RP VARIANT HPC9 GLU-84. RX PubMed=22714738; DOI=10.1158/1055-9965.epi-12-0495; RA Breyer J.P., Avritt T.G., McReynolds K.M., Dupont W.D., Smith J.R.; RT "Confirmation of the HOXB13 G84E germline mutation in familial prostate RT cancer."; RL Cancer Epidemiol. Biomarkers Prev. 21:1348-1353(2012). RN [12] RP INVOLVEMENT IN HPC9, AND VARIANTS HPC9 GLU-84; ASP-88; PRO-144; CYS-216 AND RP GLY-229. RX PubMed=22236224; DOI=10.1056/nejmoa1110000; RA Ewing C.M., Ray A.M., Lange E.M., Zuhlke K.A., Robbins C.M., Tembe W.D., RA Wiley K.E., Isaacs S.D., Johng D., Wang Y., Bizon C., Yan G., Gielzak M., RA Partin A.W., Shanmugam V., Izatt T., Sinari S., Craig D.W., Zheng S.L., RA Walsh P.C., Montie J.E., Xu J., Carpten J.D., Isaacs W.B., Cooney K.A.; RT "Germline mutations in HOXB13 and prostate-cancer risk."; RL N. Engl. J. Med. 366:141-149(2012). RN [13] RP INVOLVEMENT IN HPC9, AND VARIANT HPC9 GLU-84. RX PubMed=23292082; DOI=10.1158/1055-9965.epi-12-1000-t; RA Laitinen V.H., Wahlfors T., Saaristo L., Rantapero T., Pelttari L.M., RA Kilpivaara O., Laasanen S.L., Kallioniemi A., Nevanlinna H., Aaltonen L., RA Vessella R.L., Auvinen A., Visakorpi T., Tammela T.L., Schleutker J.; RT "HOXB13 G84E mutation in Finland: population-based analysis of prostate, RT breast, and colorectal cancer risk."; RL Cancer Epidemiol. Biomarkers Prev. 22:452-460(2013). RN [14] RP INVOLVEMENT IN HPC9, AND VARIANT HPC9 GLU-84. RX PubMed=23064873; DOI=10.1007/s00439-012-1229-4; RG International Consortium for Prostate Cancer Genetics; RA Xu J., Lange E.M., Lu L., Zheng S.L., Wang Z., Thibodeau S.N., RA Cannon-Albright L.A., Teerlink C.C., Camp N.J., Johnson A.M., Zuhlke K.A., RA Stanford J.L., Ostrander E.A., Wiley K.E., Isaacs S.D., Walsh P.C., RA Maier C., Luedeke M., Vogel W., Schleutker J., Wahlfors T., Tammela T., RA Schaid D., McDonnell S.K., DeRycke M.S., Cancel-Tassin G., Cussenot O., RA Wiklund F., Gronberg H., Eeles R., Easton D., Kote-Jarai Z., RA Whittemore A.S., Hsieh C.L., Giles G.G., Hopper J.L., Severi G., RA Catalona W.J., Mandal D., Ledet E., Foulkes W.D., Hamel N., Mahle L., RA Moller P., Powell I., Bailey-Wilson J.E., Carpten J.D., Seminara D., RA Cooney K.A., Isaacs W.B.; RT "HOXB13 is a susceptibility gene for prostate cancer: results from the RT international consortium for prostate cancer genetics (ICPCG)."; RL Hum. Genet. 132:5-14(2013). RN [15] RP INVOLVEMENT IN HPC9, AND VARIANT HPC9 GLU-84. RX PubMed=25629170; DOI=10.1371/journal.pgen.1004930; RA Hoffmann T.J., Sakoda L.C., Shen L., Jorgenson E., Habel L.A., Liu J., RA Kvale M.N., Asgari M.M., Banda Y., Corley D., Kushi L.H., RA Quesenberry C.P. Jr., Schaefer C., Van Den Eeden S.K., Risch N., RA Witte J.S.; RT "Imputation of the Rare HOXB13 G84E Mutation and Cancer Risk in a Large RT Population-Based Cohort."; RL PLoS Genet. 11:E1004930-E1004930(2015). RN [16] RP VARIANT HPC9 GLU-84, AND VARIANT CYS-217. RX PubMed=27424772; DOI=10.1038/srep30026; RA Liu J., Prager-van der Smissen W.J., Schmidt M.K., Collee J.M., RA Cornelissen S., Lamping R., Nieuwlaat A., Foekens J.A., Hooning M.J., RA Verhoef S., van den Ouweland A.M., Hogervorst F.B., Martens J.W., RA Hollestelle A.; RT "Recurrent HOXB13 mutations in the Dutch population do not associate with RT increased breast cancer risk."; RL Sci. Rep. 6:30026-30026(2016). CC -!- FUNCTION: Sequence-specific transcription factor which is part of a CC developmental regulatory system that provides cells with specific CC positional identities on the anterior-posterior axis. Binds CC preferentially to methylated DNA (PubMed:28473536). CC {ECO:0000269|PubMed:28473536}. CC -!- SUBUNIT: Heterodimer with MEIS1 (PubMed:28473536). Heterodimer with CC MEIS2 (Ref.8). {ECO:0000269|PubMed:28473536, ECO:0000269|Ref.8}. CC -!- INTERACTION: CC Q92826; Q92993: KAT5; NbExp=3; IntAct=EBI-11317274, EBI-399080; CC Q92826; Q8TAP4-4: LMO3; NbExp=3; IntAct=EBI-11317274, EBI-11742507; CC Q92826; P17252: PRKCA; NbExp=3; IntAct=EBI-11317274, EBI-1383528; CC Q92826; Q15047-2: SETDB1; NbExp=3; IntAct=EBI-11317274, EBI-9090795; CC Q92826; P61981: YWHAG; NbExp=3; IntAct=EBI-11317274, EBI-359832; CC -!- SUBCELLULAR LOCATION: Nucleus. CC -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in CC tissues of the prostate. Most prostate cancers are adenocarcinomas that CC develop in the acini of the prostatic ducts. Other rare histopathologic CC types of prostate cancer that occur in approximately 5% of patients CC include small cell carcinoma, mucinous carcinoma, prostatic ductal CC carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal CC cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:22236224, CC ECO:0000269|PubMed:22714738, ECO:0000269|PubMed:23064873, CC ECO:0000269|PubMed:23292082, ECO:0000269|PubMed:25629170, CC ECO:0000269|PubMed:27424772}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the Abd-B homeobox family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U57052; AAC50664.1; -; mRNA. DR EMBL; U81599; AAB39863.1; -; mRNA. DR EMBL; BT007410; AAP36078.1; -; mRNA. DR EMBL; AK313266; BAG36075.1; -; mRNA. DR EMBL; CH471109; EAW94714.1; -; Genomic_DNA. DR EMBL; BC007092; AAH07092.1; -; mRNA. DR EMBL; BC070233; AAH70233.1; -; mRNA. DR CCDS; CCDS11536.1; -. DR RefSeq; NP_006352.2; NM_006361.5. DR PDB; 2CRA; NMR; -; A=217-273. DR PDB; 5EDN; X-ray; 3.20 A; A/B/G/J=209-284. DR PDB; 5EEA; X-ray; 2.19 A; A/B/G/J=217-279. DR PDB; 5EF6; X-ray; 3.00 A; A/B/G/J=217-278. DR PDB; 5EG0; X-ray; 3.10 A; B=217-277. DR PDB; 5EGO; X-ray; 2.54 A; B=217-277. DR PDB; 5NO6; X-ray; 2.88 A; A/B=217-278. DR PDB; 7PSX; X-ray; 2.00 A; A/B/G/J=217-277. DR PDBsum; 2CRA; -. DR PDBsum; 5EDN; -. DR PDBsum; 5EEA; -. DR PDBsum; 5EF6; -. DR PDBsum; 5EG0; -. DR PDBsum; 5EGO; -. DR PDBsum; 5NO6; -. DR PDBsum; 7PSX; -. DR AlphaFoldDB; Q92826; -. DR SMR; Q92826; -. DR BioGRID; 115744; 23. DR IntAct; Q92826; 17. DR MINT; Q92826; -. DR STRING; 9606.ENSP00000290295; -. DR iPTMnet; Q92826; -. DR PhosphoSitePlus; Q92826; -. DR SwissPalm; Q92826; -. DR BioMuta; HOXB13; -. DR DMDM; 50403792; -. DR jPOST; Q92826; -. DR MassIVE; Q92826; -. DR MaxQB; Q92826; -. DR PaxDb; 9606-ENSP00000290295; -. DR PeptideAtlas; Q92826; -. DR ProteomicsDB; 75504; -. DR Antibodypedia; 3837; 297 antibodies from 29 providers. DR DNASU; 10481; -. DR Ensembl; ENST00000290295.8; ENSP00000290295.8; ENSG00000159184.8. DR GeneID; 10481; -. DR KEGG; hsa:10481; -. DR MANE-Select; ENST00000290295.8; ENSP00000290295.8; NM_006361.6; NP_006352.2. DR UCSC; uc002ioa.4; human. DR AGR; HGNC:5112; -. DR CTD; 10481; -. DR DisGeNET; 10481; -. DR GeneCards; HOXB13; -. DR HGNC; HGNC:5112; HOXB13. DR HPA; ENSG00000159184; Group enriched (intestine, prostate). DR MalaCards; HOXB13; -. DR MIM; 176807; phenotype. DR MIM; 604607; gene. DR MIM; 610997; phenotype. DR neXtProt; NX_Q92826; -. DR OpenTargets; ENSG00000159184; -. DR Orphanet; 1331; Familial prostate cancer. DR PharmGKB; PA29388; -. DR VEuPathDB; HostDB:ENSG00000159184; -. DR eggNOG; KOG0487; Eukaryota. DR GeneTree; ENSGT00940000159029; -. DR HOGENOM; CLU_059940_1_0_1; -. DR InParanoid; Q92826; -. DR OMA; HPPDGCA; -. DR OrthoDB; 728401at2759; -. DR PhylomeDB; Q92826; -. DR TreeFam; TF330813; -. DR PathwayCommons; Q92826; -. DR SignaLink; Q92826; -. DR SIGNOR; Q92826; -. DR BioGRID-ORCS; 10481; 35 hits in 1172 CRISPR screens. DR ChiTaRS; HOXB13; human. DR EvolutionaryTrace; Q92826; -. DR GeneWiki; HOXB13; -. DR GenomeRNAi; 10481; -. DR Pharos; Q92826; Tbio. DR PRO; PR:Q92826; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q92826; Protein. DR Bgee; ENSG00000159184; Expressed in rectum and 21 other tissues. DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005667; C:transcription regulator complex; IEA:Ensembl. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:NTNU_SB. DR GO; GO:0008327; F:methyl-CpG binding; IDA:UniProtKB. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central. DR GO; GO:0043565; F:sequence-specific DNA binding; IDA:NTNU_SB. DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL. DR GO; GO:0001525; P:angiogenesis; IEP:UniProtKB. DR GO; GO:0008544; P:epidermis development; TAS:ProtInc. DR GO; GO:0060743; P:epithelial cell maturation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:NTNU_SB. DR GO; GO:0060527; P:prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis; IEA:Ensembl. DR GO; GO:0040008; P:regulation of growth; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR GO; GO:0033574; P:response to testosterone; IEA:Ensembl. DR GO; GO:0009611; P:response to wounding; TAS:ProtInc. DR CDD; cd00086; homeodomain; 1. DR Gene3D; 1.10.10.60; Homeodomain-like; 1. DR InterPro; IPR009057; Homeobox-like_sf. DR InterPro; IPR017970; Homeobox_CS. DR InterPro; IPR001356; Homeobox_dom. DR InterPro; IPR022067; HoxA13_N. DR PANTHER; PTHR45804:SF6; HOMEOBOX PROTEIN HOX-B13; 1. DR PANTHER; PTHR45804; SEGMENTATION PROTEIN FUSHI TARAZU-LIKE PROTEIN; 1. DR Pfam; PF00046; Homeodomain; 1. DR Pfam; PF12284; HoxA13_N; 1. DR SMART; SM00389; HOX; 1. DR SUPFAM; SSF46689; Homeodomain-like; 1. DR PROSITE; PS00027; HOMEOBOX_1; 1. DR PROSITE; PS50071; HOMEOBOX_2; 1. DR Genevisible; Q92826; HS. PE 1: Evidence at protein level; KW 3D-structure; Developmental protein; Disease variant; DNA-binding; KW Homeobox; Nucleus; Reference proteome; Transcription; KW Transcription regulation. FT CHAIN 1..284 FT /note="Homeobox protein Hox-B13" FT /id="PRO_0000200160" FT DNA_BIND 216..275 FT /note="Homeobox" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00108" FT REGION 217..246 FT /note="Interaction with DNA" FT /evidence="ECO:0000305|PubMed:28473536, ECO:0000305|Ref.8" FT REGION 258..269 FT /note="Interaction with 5-mCpG DNA" FT /evidence="ECO:0000305|PubMed:28473536" FT REGION 270..273 FT /note="Interaction with DNA" FT /evidence="ECO:0000305|PubMed:28473536, ECO:0000305|Ref.8" FT VARIANT 41 FT /note="T -> M (in dbSNP:rs199799743)" FT /evidence="ECO:0000269|PubMed:11857506" FT /id="VAR_031849" FT VARIANT 84 FT /note="G -> E (risk factor for HPC9; dbSNP:rs138213197)" FT /evidence="ECO:0000269|PubMed:22236224, FT ECO:0000269|PubMed:22714738, ECO:0000269|PubMed:23064873, FT ECO:0000269|PubMed:23292082, ECO:0000269|PubMed:25629170, FT ECO:0000269|PubMed:27424772" FT /id="VAR_071866" FT VARIANT 88 FT /note="Y -> D (in HPC9; uncertain significance)" FT /evidence="ECO:0000269|PubMed:22236224" FT /id="VAR_071867" FT VARIANT 144 FT /note="L -> P (in HPC9; uncertain significance)" FT /evidence="ECO:0000269|PubMed:22236224" FT /id="VAR_071868" FT VARIANT 216 FT /note="G -> C (in HPC9; uncertain significance; FT dbSNP:rs375917549)" FT /evidence="ECO:0000269|PubMed:22236224" FT /id="VAR_071869" FT VARIANT 217 FT /note="R -> C (in dbSNP:rs139475791)" FT /evidence="ECO:0000269|PubMed:27424772" FT /id="VAR_077246" FT VARIANT 229 FT /note="R -> G (in HPC9; uncertain significance; FT dbSNP:rs529100627)" FT /evidence="ECO:0000269|PubMed:22236224" FT /id="VAR_071870" FT CONFLICT 138..139 FT /note="QP -> HA (in Ref. 1 and 2)" FT /evidence="ECO:0000305" FT CONFLICT 211 FT /note="C -> S (in Ref. 1; AAC50664)" FT /evidence="ECO:0000305" FT HELIX 225..237 FT /evidence="ECO:0007829|PDB:5EEA" FT HELIX 243..253 FT /evidence="ECO:0007829|PDB:5EEA" FT HELIX 257..275 FT /evidence="ECO:0007829|PDB:5EEA" SQ SEQUENCE 284 AA; 30676 MW; 3EE5898449C33CFE CRC64; MEPGNYATLD GAKDIEGLLG AGGGRNLVAH SPLTSHPAAP TLMPAVNYAP LDLPGSAEPP KQCHPCPGVP QGTSPAPVPY GYFGGGYYSC RVSRSSLKPC AQAATLAAYP AETPTAGEEY PSRPTEFAFY PGYPGTYQPM ASYLDVSVVQ TLGAPGEPRH DSLLPVDSYQ SWALAGGWNS QMCCQGEQNP PGPFWKAAFA DSSGQHPPDA CAFRRGRKKR IPYSKGQLRE LEREYAANKF ITKDKRRKIS AATSLSERQI TIWFQNRRVK EKKVLAKVKN SATP //